Other News To Note

PolyMedix Inc., of Radnor, Pa., announced that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity in an in vitro laboratory test against the NDM-1 drug-resistant strain of Klebsiella pneumonia. PMX-30063 also is in a Phase II trial in patients for treatment of acute bacterial skin and skin structure Infections caused by staph bacteria, the company said.